Display options
Cite
Jain S, Singhal S, Lee P, et al. Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010;2(1):105-18
Jain, S., Singhal, S., Lee, P., & Xu, R. (2010). Molecular genetics of hepatocellular neoplasia. American journal of translational research, 2(1), 105-18.
Jain, Shilpa, et al. "Molecular genetics of hepatocellular neoplasia." American journal of translational research vol. 2,1 (2010): 105-18.
Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010 Jan 23;2(1):105-18. PMID: 20182587; PMCID: PMC2826827.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2010 Jan 23;2(1):105-18.

Molecular genetics of hepatocellular neoplasia.

American journal of translational research

Shilpa Jain, Shashideep Singhal, Peng Lee, Ruliang Xu

PMID: 20182587 PMCID: PMC2826827

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the third leading cause of cancer deaths worldwide. Proper classification and early identification of HCC and precursor lesions is essential to the successful treatment and survival of HCC patients. Recent molecular genetic, pathologic, and clinical data have led to the stratification of hepatic adenomas into three subgroups: those with mutant TCF1/HNF1 alpha gene, those with mutant beta-catenin, and those without mutations in either of these loci. Hepatic adenomas with alpha-catenin mutations have a significantly greater risk for malignant transformation in comparison with the other two subgroups. Telangiectatic focal nodular hyperplasia has now been reclassified as telangiectatic adenoma due to the presence of non-random methylation patterns, consistent with the monoclonal origin which is similar to hepatic adenoma and HCC. HCC precursor lesions demonstrate unique molecular alterations of HSP70, CAP2, glypican 3, and glutamine synthetase that have proven useful in the histologic diagnosis of early HCC. Though specific genetic alterations depend on HCC etiology, the main proteins affected include cell membrane receptors (in particular tyrosine kinase receptors) as well as proteins involved in cell signaling (specifically Wnt/beta-catenin, Ras/Raf/MEK/ERK and PI3K/Akt/mTOR pathways), cell cycle regulation (i.e. p53, p16/INK4, cyclin/cdk complex), invasiveness (EMT, TGF-beta) and DNA metabolism. Advances in gene expression profiling have provided new insights into the molecular genetics of HCC. HCCs can now be stratified into two clinically relevant groups: Class A, the low survival subclass (overall survival time 30.3+/- 8.02 months), shows strong expression signatures of cell proliferation and antiapoptosis genes (such as PNCA and cell cycle regulators CDK4, CCNB1, CCNA2, and CKS2) as well as genes involving ubiquitination and sumoylation; Class B, the high survival subclass (overall survival time 83.7 +/-10.3 months), does not have the above expression signature. In fact, insights into HCC-specific alterations of signal transduction pathways and protein expression patterns have led to the development of new therapeutic agents with molecular targets such as EGFR, VEGF, or other multi-kinase inhibitors. In the future, these specific molecular alterations in HCC can potentially serve as diagnostic tools, prognostic markers, and/or therapeutic targets with the potential to alter clinical outcomes.

Keywords: CAP2; HSP70; Molecular genetics; glutamine synthetase; glypican 3; hepatocellular carcinoma; liver cancer; β-catenin

References

  1. Am J Pathol. 2003 Jun;162(6):1823-9 - PubMed
  2. Ann Acad Med Singap. 1996 Jan;25(1):22-30 - PubMed
  3. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  4. Oncogene. 1997 Jun 19;14(24):2927-33 - PubMed
  5. J Cancer Res Clin Oncol. 2003 Jan;129(1):43-51 - PubMed
  6. Oncogene. 1999 Aug 19;18(33):4726-33 - PubMed
  7. Ann Hepatol. 2006 Jan-Mar;5(1):16-24 - PubMed
  8. Semin Surg Oncol. 1996 May-Jun;12(3):155-9 - PubMed
  9. Pathologica. 2003 Apr;95(2):71-82 - PubMed
  10. Am J Gastroenterol. 2003 Feb;98(2):442-7 - PubMed
  11. J Cancer Res Clin Oncol. 2002 Jul;128(7):369-79 - PubMed
  12. J Natl Cancer Inst. 2000 Jan 19;92(2):148-53 - PubMed
  13. Hepatology. 2004 Sep;40(3):667-76 - PubMed
  14. Gut. 2003 Aug;52(8):1178-81 - PubMed
  15. World J Gastroenterol. 2003 Apr;9(4):692-5 - PubMed
  16. J Exp Med. 1998 Jul 20;188(2):341-50 - PubMed
  17. Oncogene. 2001 Jun 21;20(28):3674-82 - PubMed
  18. Ann Acad Med Singap. 1999 Jan;28(1):67-71 - PubMed
  19. N Engl J Med. 1976 Feb 26;294(9):470-2 - PubMed
  20. World J Gastroenterol. 2003 Jun;9(6):1202-7 - PubMed
  21. Nature. 1996 Dec 5;384(6608):455-8 - PubMed
  22. Jpn J Cancer Res. 1999 Aug;90(8):824-8 - PubMed
  23. Cancer Lett. 2000 Jan 1;148(1):73-80 - PubMed
  24. Lancet Oncol. 2009 Aug;10(8):794-800 - PubMed
  25. Semin Cancer Biol. 2000 Jun;10(3):185-200 - PubMed
  26. Oncogene. 2000 Aug 3;19(33):3733-8 - PubMed
  27. Oncogene. 1999 Nov 11;18(47):6583-8 - PubMed
  28. J Gastroenterol Hepatol. 2003 Apr;18(4):430-6 - PubMed
  29. Nat Genet. 2002 Oct;32(2):312-5 - PubMed
  30. Hepatology. 2007 Jan;45(1):42-52 - PubMed
  31. Hepatology. 2001 Apr;33(4):832-40 - PubMed
  32. J Gastroenterol. 2001 Oct;36(10):651-60 - PubMed
  33. Int J Cancer. 2003 Sep 1;106(3):334-41 - PubMed
  34. Hepatology. 1993 Apr;17(4):621-7 - PubMed
  35. Gastroenterology. 1999 Jul;117(1):154-60 - PubMed
  36. Onkologie. 2008 Oct;31(10):550-5 - PubMed
  37. Mutat Res. 2000 Apr;462(2-3):311-22 - PubMed
  38. Cancer Res. 2008 Aug 15;68(16):6779-88 - PubMed
  39. Curr Cancer Drug Targets. 2009 Sep;9(6):738-47 - PubMed
  40. Oncology. 2001;60(4):346-54 - PubMed
  41. Genes Chromosomes Cancer. 1995 Jul;13(3):163-7 - PubMed
  42. Arch Surg. 2000 Nov;135(11):1329-33 - PubMed
  43. Anticancer Res. 2001 Jul-Aug;21(4A):2429-33 - PubMed
  44. Clin Cancer Res. 2003 Aug 15;9(9):3389-96 - PubMed
  45. Teratog Carcinog Mutagen. 2003;Suppl 1:161-70 - PubMed
  46. Am J Pathol. 2000 Sep;157(3):763-70 - PubMed
  47. Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23 - PubMed
  48. Cancer Res. 2006 Dec 15;66(24):11851-8 - PubMed
  49. Semin Liver Dis. 1984 May;4(2):122-35 - PubMed
  50. J Nutr. 2001 May;131(5):1427-32 - PubMed
  51. Lancet. 2003 Mar 15;361(9361):923-9 - PubMed
  52. Semin Cancer Biol. 2000 Jun;10(3):241-9 - PubMed
  53. Cancer Lett. 2007 Jun 8;250(2):284-91 - PubMed
  54. J Hepatol. 1997 Oct;27(4):669-76 - PubMed
  55. J Clin Invest. 2006 Jun;116(6):1582-95 - PubMed
  56. Hepatol Res. 2010 Jan 1;40(1):49-60 - PubMed
  57. Oncogene. 1991 May;6(5):765-70 - PubMed
  58. Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91 - PubMed
  59. Cancer Res. 2000 Dec 1;60(23):6581-4 - PubMed
  60. Hepatology. 2008 Mar;47(3):897-907 - PubMed
  61. Clin Cancer Res. 2009 Aug 15;15(16):5073-81 - PubMed
  62. J Virol. 1997 Dec;71(12):9417-26 - PubMed
  63. Hepatology. 2000 Nov;32(5):970-9 - PubMed
  64. Hum Mutat. 2003 Mar;21(3):201-16 - PubMed
  65. Cancer Res. 2003 Jun 15;63(12):3043-8 - PubMed
  66. Lancet. 1991 Nov 30;338(8779):1356-9 - PubMed
  67. Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10350-4 - PubMed
  68. Oncogene. 2008 Sep 25;27(43):5651-61 - PubMed
  69. Cancer. 2001 Jul 1;92(1):136-45 - PubMed
  70. Neoplasia. 2005 Apr;7(4):348-55 - PubMed
  71. Cancer Res. 1994 Aug 1;54(15):4177-82 - PubMed
  72. Mol Cell Biol. 1994 Feb;14(2):989-98 - PubMed
  73. Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1003-7 - PubMed
  74. Hepatology. 2000 Nov;32(5):942-6 - PubMed
  75. Proc Natl Acad Sci U S A. 2002 May 14;99(10):6655-60 - PubMed
  76. Gastroenterology. 2007 Aug;133(2):647-58 - PubMed
  77. Adv Exp Med Biol. 2002;504:229-33 - PubMed
  78. Oncogene. 1993 Aug;8(8):2303-6 - PubMed
  79. Oncol Res. 2000;12(2):59-69 - PubMed
  80. Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 - PubMed
  81. Arch Intern Med. 2000 Nov 27;160(21):3227-30 - PubMed
  82. Cancer Lett. 2003 Feb 20;190(2):213-9 - PubMed
  83. BioDrugs. 2009;23(6):377-89 - PubMed
  84. Histol Histopathol. 2003 Jul;18(3):897-909 - PubMed
  85. Hepatogastroenterology. 1998 Sep-Oct;45(23):1753-9 - PubMed
  86. Cancer Lett. 2002 Aug 28;182(2):193-202 - PubMed
  87. J Virol. 1996 Jul;70(7):4558-66 - PubMed
  88. Gastroenterology. 1985 Nov;89(5):1132-8 - PubMed
  89. Eur J Cancer. 1999 Apr;35(4):652-8 - PubMed
  90. World J Gastroenterol. 2009 Oct 7;15(37):4695-708 - PubMed
  91. J Med Virol. 1994 Sep;44(1):67-73 - PubMed
  92. Gastroenterology. 2003 Nov;125(5):1470-5 - PubMed
  93. Hepatology. 1996 Sep;24(3):575-9 - PubMed
  94. Cancer. 2007 Sep 1;110(5):1059-67 - PubMed
  95. Expert Rev Mol Diagn. 2002 Mar;2(2):120-8 - PubMed
  96. Am J Pathol. 2003 Mar;162(3):991-1000 - PubMed
  97. Carcinogenesis. 1997 Jan;18(1):59-81 - PubMed
  98. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  99. Clin Liver Dis. 2002 May;6(2):497-512 - PubMed
  100. Semin Cancer Biol. 2000 Jun;10(3):211-31 - PubMed
  101. Mol Cells. 2002 Dec 31;14(3):382-7 - PubMed
  102. Biochem Biophys Res Commun. 2001 Mar 30;282(2):647-54 - PubMed
  103. Cancer Res. 2007 Jul 1;67(13):6092-9 - PubMed
  104. J Pathol. 2001 Jan;193(1):95-101 - PubMed
  105. N Engl J Med. 2008 Nov 6;359(19):1995-2004 - PubMed
  106. Gastroenterology. 2005 May;128(5):1211-8 - PubMed
  107. Cancer Res. 1993 Jun 15;53(12):2884-7 - PubMed
  108. Intervirology. 2008;51 Suppl 1:42-5 - PubMed
  109. Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):155-61 - PubMed
  110. Oncogene. 2001 Sep 27;20(43):6233-40 - PubMed
  111. Mod Pathol. 2006 Aug;19(8):1108-16 - PubMed
  112. Oncogene. 2006 Oct 5;25(45):6056-66 - PubMed
  113. J Cell Mol Med. 2008 Dec;12(6A):2189-204 - PubMed
  114. Oncogene. 2003 Aug 11;22(33):5093-107 - PubMed
  115. Carcinogenesis. 2001 Apr;22(4):535-45 - PubMed
  116. Oncogene. 1997 Jan 30;14(4):395-404 - PubMed
  117. Lancet. 1990 Nov 10;336(8724):1150-3 - PubMed
  118. Cancer Cell. 2006 Aug;10(2):99-111 - PubMed
  119. J Hepatobiliary Pancreat Surg. 2002;9(3):304-11 - PubMed
  120. Cancer. 2007 Aug 1;110(3):581-9 - PubMed
  121. Mol Cell Biol. 1998 Mar;18(3):1562-9 - PubMed
  122. Cancer Lett. 1994 Aug 15;83(1-2):197-200 - PubMed
  123. Hepatology. 2007 Aug;46(2):436-45 - PubMed
  124. Hepatology. 2006 Mar;43(3):515-24 - PubMed
  125. Gastroenterology. 2007 Nov;133(5):1475-86 - PubMed
  126. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10 - PubMed
  127. J Virol. 1999 Sep;73(9):7231-40 - PubMed
  128. Science. 1994 May 27;264(5163):1317-9 - PubMed
  129. J Gastroenterol. 2009;44 Suppl 19:136-41 - PubMed
  130. Hepatology. 2000 Apr;31(4):846-50 - PubMed
  131. Cancer Res. 2001 Mar 1;61(5):2129-37 - PubMed
  132. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8162-7 - PubMed
  133. Int J Oncol. 2002 Jun;20(6):1173-8 - PubMed
  134. Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17216-21 - PubMed
  135. N Engl J Med. 1978 Aug 3;299(5):239-41 - PubMed
  136. Int J Oncol. 2000 Mar;16(3):543-7 - PubMed
  137. Cancer Res. 1994 Jan 1;54(1):231-5 - PubMed
  138. Cancer Res. 2003 Feb 15;63(4):859-64 - PubMed
  139. Int J Oncol. 2004 Jan;24(1):43-8 - PubMed
  140. Cancer Res. 2001 May 15;61(10):4238-43 - PubMed
  141. Adv Virus Res. 1996;47:253-302 - PubMed
  142. Cancer Res. 2002 Jul 15;62(14):3939-44 - PubMed
  143. Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15089-94 - PubMed
  144. Hepatology. 1999 Jun;29(6):1858-62 - PubMed
  145. Int J Oncol. 2000 Sep;17(3):507-12 - PubMed
  146. Langenbecks Arch Surg. 2000 Apr;385(3):154-61 - PubMed
  147. Genes Chromosomes Cancer. 2001 Jan;30(1):110 - PubMed
  148. Toxicology. 2002 Dec 27;181-182:43-7 - PubMed
  149. Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14707-12 - PubMed
  150. J Cancer Res Clin Oncol. 2003 May;129(5):279-86 - PubMed
  151. Oncogene. 2002 Apr 25;21(18):2926-37 - PubMed
  152. Int J Cancer. 2003 Feb 10;103(4):455-65 - PubMed
  153. Cancer Res. 2002 Aug 15;62(16):4711-21 - PubMed
  154. Hepatology. 2008 Dec;48(6):2047-63 - PubMed
  155. Gastroenterology. 2004 May;126(5):1323-9 - PubMed

Publication Types